# A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

> **NCT02922543** · — · COMPLETED · sponsor: **Celgene** · enrollment: 361 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02922543
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-18
- **Primary completion:** 2014-10-11
- **Final completion:** 2014-10-11
- **Target enrollment:** 361 (ACTUAL)
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02922543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02922543, "A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02922543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*